Prospective strategies for targeting HIV-1 integrase function

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1055-1060

  Luo, Yang ^a   Muesing, Mark A ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROINDOL 3 YL) 3 HYDROXY 3 (2H TETRAZOL 5 YL) PROPENONE; 2 (QUINOLIN 3 YL)ACETIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CHIBA 3003; CX 06378; CX 06387; ELVITEGRAVIR; INTEGRASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STYRYLQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; BINDING SITE; CATALYSIS; DNA FLANKING REGION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NOTE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; VIRUS ENTRY; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 77954663606     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.205     Document Type: Note

References (71)

1. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5, 114 (2008).
2. Espeseth AS, Felock P, Wolfe A et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl Acad. Sci. USA 97(21), 11244-11249 (2000).
3. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453), 646-650 (2000).
4. Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today 43(12), 865-877 (2007).
5. Summa V, Petrocchi A, Bonelli F et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51(18), 5843-5855 (2008).
6. Dejesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. ImmuneDefic. Syndr. 43(1), 1-5 (2006).
7. Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49(5), 1506-1508 (2006).
8. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12(4), 563-570 (2007).
9. Low A, Prada N, Topper M et al. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob. Agents Che-mother. 53(10), 4275-4282 (2009).
10. Garrido C, Geretti AM, Zahonero N et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Che-mother. 65(2), 320-326 (2010).
11. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. Natural polymorphisms of integrase among HIV type 1-infected south african patients. AIDS Res. Hum. Retroviruses 26(4), 489-493 (2010).
12. Charpentier C, Laureillard D, Piketty C et al. High frequency of integrase q148r minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 24(6), 867-87 (2010).
13. Guiot E, Carayon K, Delelis O et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 281(32), 22707-22719 (2006).
14. Hare S, Di Nunzio F, Labeja A, Wang J, Engelman A, Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. PLoSPathog. 5(7), e1000515 (2009).
15. Cherepanov P. Integrase illuminated. EMBO Rep. 11(5), 328 (2010).
16. Craigie R. Structural biology: when four become one. Nature 464(7286), 167-168 (2010).
17. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464(7286), 232-236 (2010).
18. Pandey KK, Bera S, Zahm J et al. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J. Virol. 81(22), 12189-12199 (2007).
19. Zahm JA, Bera S, Pandey KK et al. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob. Agents Chemother. 52(9), 3358-3368 (2008).
20. Valkov E, Gupta SS, Hare S et al. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 37(1), 243-255 (2009).
21. Chow YK, Hirsch MS, Merrill DP et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361(6413), 650-654 (1993).
22. Deprez E, Barbe S, Kolaski M et al. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65(1), 85-98 (2004).
23. Bonnenfant S, Thomas CM, Vita C et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 78(11), 5728-5736 (2004).
24. Mousnier A, Leh H, Mouscadet JF, Dargemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 66(4), 783-788 (2004). (Pubitemid 39319449)
25. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83(22), 11440-11446 (2009).
26. Goethals O, Vos A, Van Ginderen M et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibito with second-generation resistance profiles. Virology, 402(2), 338-346 (2010).
27. Da Silva D, Van Wesenbeeck L, Breilh D et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegrav containing regimens. J. Antimicrob. Chemother. 65(6), 1262-1269 (2010).
28. Marchand C, Zhang X, Pais GC et al. Structural determinants for HIV-1 integrase inhibition by p-diketo acids. J. Biol. Chem. 277(15), 12596-12603 (2002).
29. Maroun RG, Gayet S, Benleulmi MS et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemist 40(46), 13840-13848 (2001).
30. Sourgen F, Maroun Rg, Frere V et al. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results. Eur. J. Biochem. 240(3 765-773 (1996).
31. Hayouka Z, Levin A, Maes M et al. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem. Biophys. Res. Commun. 394(2), 260-265 (2010).
32. Hayouka Z, Rosenbluh J, Levin A et al. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. NatlAcat Sci. USA 104(20), 8316-8321 (2007).
33. De Luca L, Barreca Ml, Ferro S et al. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 4(8), 1311-1316 (2009).
34. Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. Peptide inhibitors of HIV-1 integrase: from mechanistic studies t improved lead compounds. Bioorg. Med. Chem. 17(22), 7635-7642 (2009).
35. Kessl JJ, Eidahl JO, Shkriabai N et al. An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule . Mol. Pharmacol. 76(4), 824-832 (2009).
36. Priet S, Navarro JM, Gros N, Querat G, Sir J. Functional role of HIV-1 virion-associated uracil DNA glycosylase 2 in the correction o G:U mispairs to G:C pairs. J. Biol. Chem. 278(7), 4566-4571 (2003).
37. Priet S, Gros N, Navarro JM et al. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle Mol. Cell 17(4), 479-490 (2005).
38. Williams Kl, Zhang Y, Shkriabai N et al. Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5'-phosphate complex reveals a new binding site for a nucleotide inhibitor. J. Biol. Chem. 280(9), 7949-7955 (2005).
39. De Rijck J, Vandekerckhove L, Gijsbers R et al. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 80(23), 11498-11509 (2006).
40. Llano M, Saenz DT, Meehan A et al. An essential role for LEDGF/p75 in HIV integration. Science 314(5798), 461-464 (2006).
41. Vandekerckhove L, Christ F, Van Maele B et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol. 80(4), 1886-1896 (2006).
42. Emiliani S, Mousnier A, Busschots K et al. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 280(27), 25517-25523 (2005).
43. Maertens G, Cherepanov P, Pluymers W et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278(35), 33528-33539 (2003). (Pubitemid 37055807)
44. Meehan AM, Poeschla EM. Chromatin tethering and retroviral integration: recent discoveries and parallels with DNA viruses. Biochim. Biophys. Acta 1799(3-4), 182-191 (2010).
45. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl Acad. Sci. USA 102(48), 17308-17313 (2005).
46. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, Poeschla E. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J. Cell Sci. 118(8), 1733-1743 (20 05).
47. Cherepanov P, Devroe E, Silver PA, Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/ transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 279(47), 48883-48892 (2004).
48. Hare S, Shun MC, Gupta SS, Valkov E, Engelman A, Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 5(1), e1000259 (2009).
49. Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the ledgf/p75-integrase interaction and hiv replication. Nat. Chem. Biol. 6(6), 442-448 (2010).
50. Christ F, Voet A, Marchand A, Others A. First-in-class inhibitors of LEDGF/p75-integrase interaction and HIV replication. Presented at: 17th Conference on Retroviruses & Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
51. Zheng Y, Ao Z, Danappa Jayappa K, Yao X. Characterization of the HIV-1 integrase chromatin- and ledgf/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase. Virol J. 7(1), 68 (2010)
52. Vandegraaff N, Devroe E, Turlure F, Silver PA, Engelman A. Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/ p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication. Virology 346(2), 415-426 (2006).
53. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 266(5193), 2002-2006 (1994).
54. Lloyd AG, Tateishi S, Bieniasz PD, Muesing MA, Yamaizumi M, Mulder LC. Effect of DNA repair protein RAD18 on viral infection. PLoS Pathog. 2(5), e40 (2006).
55. Mulder LC, Chakrabarti LA, Muesing MA. Interaction of HIV-1 integrase with DNA repair protein hRAD18. J. Biol. Chem. 277(30), 27489-27493 (2002).
56. Cherepanov P, Maertens G, Proost P et al. HIV-1 integrase forms stable tetramers and associates withLEDGF/p75 protein in human cells. J. Biol. Chem. 278(1), 372-381 (2003).
57. Violot S, Hong SS, Rakotobe D et al. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J. Virol. 77(23), 12507-12522 (2003).
58. Ao Z, Huang G, Yao H et al. Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. J. Biol. Chem. 282(18), 13456-13467 (2007).
59. Hamamoto S, Nishitsuji H, Amagasa T, Kannagi M, Masuda T. Identification of a novel human immunodeficiency virus type 1 integrase interactor, Gemin2, that facilitates efficient viral cDNA synthesis in vivo. J. Virol. 80(12), 5670-5677 (2006).
60. Tasaki T, Mulder LC, Iwamatsu A et al. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize n-degrons. Mol. Cell Biol. 25(16), 7120-7136 (2005).
61. Luo K, Wang T, Liu B et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81(13), 7238-7248 (2007).
62. Mousnier A, Kubat N, Massias-Simon A et al. Von hippel lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc. Natl Acad. Sci. USA 104(34), 13615-13620 (2007).
63. Cereseto A, Manganaro L, Gutierrez Mi et al. Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBOJ. 24(17), 3070-3081 (2005).
64. Rain JC, Cribier A, Gerard A, Emiliani S, Benarous R. Yeast two-hybrid detection of integrase-host factor interactions. Methods 47(4), 291-297 (2009).
65. Luban J. HIV-1 infection: going nuclear with tnpo3/transportin-SR2 and integrase. Curr. Biol. 18(16), R710-713 (2008).
66. Sorin M, Cano J, Das S et al. Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog. 5(6), e1000463 (2009).
67. Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M. Concerted action of cellular JNK and PIN1 restricts HIV-1 genome integration to activated CD4 + T-lymphocytes. Nat. Med. 16(3), 329-333 (2010).
68. Levin A, Armon-Omer A, Rosenbluh J et al. Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal. Retrovirology 6, 112 (2009).
69. Mulder LC, Muesing MA. Degradation of HIV-1 integrase by the N-end rule pathway. J. Biol. Chem. 275(38), 29749-29753 (2000).
70. Terreni M, Valentini P, Liverani V et al. GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology 7, 18 (2010).
71. Topper M, Luo Y, Zhadina M, Mohammed K, Smith L, Muesing MA. Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication. J. Virol. 81(6), 3012-3017 (2007).